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Key factors driving eating behavior are hunger and satiety, which
are controlled by a complex interplay of central neurotransmitter
systems and peripheral stimuli. The lipid-derived messenger oleoy-
lethanolamide (OEA) is released by enterocytes in response to fat
intake and indirectly signals satiety to hypothalamic nuclei. Brain
histamine is released during the appetitive phase to provide a high
level of arousal in anticipation of feeding, and mediates satiety.
However, despite the possible functional overlap of satiety signals,
it is not knownwhether histamine participates in OEA-induced hypo-
phagia. Using different experimental settings and diets, we report
that the anorexiant effect of OEA is significantly attenuated in
mice deficient in the histamine-synthesizing enzyme histidine
decarboxylase (HDC-KO) or acutely depleted of histamine via
interocerebroventricular infusion of the HDC blocker α-fluorome-
thylhistidine (α-FMH). α-FMH abolished OEA-induced early occur-
rence of satiety onset while increasing histamine release in the
CNS with an H3 receptor antagonist-increased hypophagia. OEA
augmented histamine release in the cortex of fasted mice within
a time window compatible to its anorexic effects. OEA also in-
creased c-Fos expression in the oxytocin neurons of the paraven-
tricular nuclei of WT but not HDC-KO mice. The density of c-Fos
immunoreactive neurons in other brain regions that receive hista-
minergic innervation and participate in the expression of feeding
behavior was comparable in OEA-treated WT and HDC-KO mice.
Our results demonstrate that OEA requires the integrity of the
brain histamine system to fully exert its hypophagic effect and
that the oxytocin neuron-rich nuclei are the likely hypothalamic
area where brain histamine influences the central effects of OEA.
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Eating behavior is regulated by central neurotransmitter sys-tems and peripheral stimuli that interact to change the be-
havioral state and concur to alter homeostatic aspects of appetite
and energy expenditure. The fatty acid amide oleoylethanolamide
(OEA) is released by the small intestine in a stimulus-dependent
manner and suppresses food intake by activating peroxisome
proliferator-activated receptor-α (PPAR-α) (1). Systemic admin-
istration of OEA induces c-Fos mRNA expression through the
vagus nerve to the nucleus of the solitary tract (NST), supraoptic
nuclei (SON), and paraventricular hypothalamic nuclei (PVN)
and increases the expression of oxytocin (2, 3), which is involved
in the central coordination of homeostatic signals and feeding
behavior (4). However, it is not known whether OEA recruits
other neurotransmitter systems in the brain to reduce food intake.
Histaminergic neurons are clustered in the hypothalamic tuber-
omammillary nuclei (TMN). They send projections organized in
functionally distinct circuits impinging on different brain regions
(5), and their firing frequency changes according to the behav-
ioral state (6). Brain histamine plays a fundamental role in eating
behavior as it induces loss of appetite and has long been considered
a satiety signal that is released during food intake (7). Early studies
showed that treatments increasing brain histamine availability or
activating histamine H1 receptor (H1R) in the CNS suppressed food
intake (8–10), and enhanced c-Fos–like immunoreactivity in the
PVN (10), whereas H1R blockade in the ventromedial hypothala-
mus (VMH) increased both meal size and duration, and suppressed
the activity of glucose-responding neurons (11).
With these considerations in mind, we examined the hypothesis
that peripherally administered OEA engages histamine signaling in
the brain. We assessed the effect of OEA on cumulative food intake
as well as on the expression of the behavioral satiety sequence (BSS)
in mice defective in brain histamine, either because they lack the
histamine-synthesizing enzyme histidine decarboxylase (HDC) or
because acutely deprived of histamine by interocerebroventricular
(i.c.v.) infusion of HDC inhibitor α-fluoromethylhistidine (α-FMH).
We also assessed the effect of OEA following systemic adminis-
tration of the H3R antagonist ABT-239 that transiently increases
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brain histamine release (12). Finally, we determined changes in
neuronal activity by assessing the pattern of c-Fos expression in-
duced by OEA in hypothalamic brain regions controlling feeding
behavior and in brain regions regulating the motivational aspect
of foraging in both HDC-KO and WT littermates. Our findings
revealed that the anorexic effects of OEA are blunted in brain
histamine-deficient mice, and establish new functional connections
between peripherally acting hypophagic signals and brain histamine
neurotransmission.
Results
Interaction Between Brain Histamine and OEA on Food Consumption.
To test whether the integrity of the histaminergic system con-
tributes to the anorexiant effect of OEA, we used HDC-KO
mice, which are unable to synthesize histamine. OEA was
injected i.p. at 10 mg/kg to induce long-lasting appetite sup-
pression (1); it does not readily enter the CNS (13) and does not
cause taste aversion (14). Controls received equivalent volumes
of the vehicle. OEA caused a profound reduction of the total
amount of food consumed by WT mice compared with vehicle-
treated littermates within the first 60 min after injection (P <
0.001; Fig. 1A). Two-way ANOVA revealed an overall significant
difference between groups [F(time)4,170 = 133.14, P < 0.0001;
F(treatment)3,170 = 185.64, P < 0.0001; F(time × treatment)12,170 =
12.93, P > 0.0001]. As expected, vehicle-treated HDC-KO
mice consumed comparable amounts of food with respect to
WT animals (histamine-deficient mice are not hyperphagic, nor
obese up to 12 wk of age) (15), whereas the anorexic effect of
OEA was significantly diminished in HDC-KO mice (P < 0.01 at
45 min; P < 0.001 at 60 min). The effect of OEA was short lived
as no difference in food consumption was observed among ex-
perimental groups 4 h after OEA injection. Histamine-deficient
mice develop metabolic changes with age (15). Hence, to exclude
the involvement of compensatory mechanisms in HDC-KO mice,
we measured food intake also in CD1 mice that received an i.c.v.
infusion of the HDC suicide inhibitor α-FMH at a dose that
abolishes basal and stimulated histamine release (see Fig. 3B).
Mice were tested at lights off (1900 h), when they have a greater
incentive to eat and the activity of histamine neurons is higher
(16). Two-way ANOVA revealed an overall significant difference
among groups [F(treatment)3,104 = 20.67, P < 0.0001; F(time)4,104 =
121.36, P < 0.00001; F(time × treatment)12,104 = 13.30, P < 0.0001].
OEA caused a profound reduction in the total amount of food
consumed by CD1 mice that received an i.c.v. infusion of saline
(Fig. 1B). Mice in the α-FMH/vehicle group tended to eat more
than the saline/vehicle animals, although this effect did not reach
statistical significance. In α-FMH–treated mice, OEA-induced
hypophagia was significantly less prominent than in the saline/
OEA group. The effect reached statistical significance 45 min
after OEA injection (P < 0.01). The overall trend is very similar
to the results obtained with HDC-KO mice during the lights-
on phase, although during the lights-off phase all experimental
groups ate consistently larger amounts of food. We then argued
that, if OEA modulates feeding by recruiting the central hista-
mine system, augmenting histamine release pharmacologically
would potentiate the anorexic effect of exogenous OEA. We
measured food-consumption in 12 h-fasted CD1 mice treated
with a combination of OEA (10 mg/kg) and ABT-239 (3 mg/kg),
an H3R antagonist that increases histamine release by blocking H3
autoreceptors (12). Two-way ANOVA followed by Bonferroni’s
post hoc test revealed a significant difference between groups
[F(time)4,104 = 392.5, P < 0.0001; F(treatment)3,104 = 31.81, P <
0.0001; F(time × treatment)12,104 = 29.04, P < 0.0001]. Each com-
pound significantly decreased food intake and coadministration
of compounds determined a further decrease (P < 0.01 at 45 min
and P < 0.001 at 60 min; Fig. 1C). We then determined the type
of interaction between the two compounds by performing an
isobolographic analysis as described in SI Materials and Methods.
We observed a dose-dependent hypophagic effect for each com-
pound and for OEA–ABT-239 mixtures administered in fixed
ratios (Fig. S1). The ED50 and 95% confidence interval, obtained
from regressions of dose–response curves (Fig. 1 D and E), were
(in milligrams per kilogram) ED50ABT-239 = 3.262 (2.883–3.641),
ED50OEA = 5.283 (4.836–5.731), and ED50mix = 4.389 (3.727–
5.050). In the isobologram, the dose of ABT-239 needed to reach
50% of the effect is plotted on the abscissa and the isoeffective
dose of OEA on the ordinate (Fig. 1F). The straight line con-
necting these two points represents the theoretical additive effect.
A Student t test revealed no significant differences between the
experimental ED50mix and the theoretical ED50add = 4.275 (3.731–
4.813). Furthermore, the interaction index γ = 1.03 indicates an
additive interaction between OEA and ABT-239 (17).
Palatable Wet Mesh Intake and Time Spent Eating in Histamine-
Depleted Mice. Palatable wet mesh (PWM) consumption was
measured in α-FMH i.c.v.-infused mice treated with OEA during
lights off. This protocol allowed us to use the BSS paradigm to
disclose the specificity of potential anorexiant agents on sa-
tiety development (18). One-way ANOVA revealed a significant
treatment effect on PWM intake (F5,39 = 16.95, P < 0.0001; Fig.
2A) during the 40-min BSS testing. α-FMH had no effect on
consumed PWM. Post hoc comparisons revealed a significant
decrease of PWM intake in saline/OEA (5 mg/kg, P < 0.01;
10 mg/kg, P < 0.001) groups compared with controls. α-FMH–
infused mice treated with OEA did not significantly differ from
Fig. 1. Interactions between OEA and brain histamine on food consumption.
(A). Time course of the effect of systemic administration of OEA (10 mg/kg,
i.p.) or vehicle (VEH) on cumulative food intake in 12 h-fasted HDC-KO and
WT mice during the lights-on period (0900 h). Each point represents mean ±
SEM of 11–8 mice. ***P < 0.001 vs. respective controls. ###P < 0.001; ##P < 0.01
vs. OEA-treatedmiceWT or HDC-KOmice by two-way ANOVA and Bonferroni’s
test. (B) Time course of the effect of α-FMH administration (5 μg; i.c.v.) or saline
(SAL) on OEA-suppressed food intake in 12 h-fastedmice. Each point represents
mean cumulative food consumption ± SEM of seven to eight mice during the
lights-off period (1900 h). ***P < 0.001, **P < 0.01, *P < 0.5 vs. respective
controls; ##P < 0.01, #P < 0.05 vs. OEA-treated WT or α-FMH–injected mice;
two-way ANOVA and Bonferroni’s test. (C) Increased brain histamine boosts
OEA-induced suppression of food intake. Time course of 10 mg/kg OEA and
3 mg/kg ABT-239 effects on cumulative food intake in 12 h-fasted CD1 mice
during the lights-on period (0900 h). Each point represents mean ± SEM
of seven to eight mice. ***P < 0.001, **P < 0.01, OEA and ABT-239 vs.
respective controls; ###P < 0.001; ##P < 0.01, ABT-239/OEA vs. saline/OEA.
(D and E) Sigmoidal and log-derived dose–response curves for OEA, ABT-239,
and the combined compounds. Each point represents mean cumulative food
consumption ±SEM of seven to nine mice expressed as percent food con-
sumption of vehicles. (F) Isobologram for OEA–ABT-239 combined effects on
food consumption.
11528 | www.pnas.org/cgi/doi/10.1073/pnas.1322016111 Provensi et al.
controls in the amount of PWM consumed (Fig. 2A). Moreover,
one-way ANOVA disclosed a significant treatment effect on
time spent eating over the 40-min BSS test (F5,39 = 8.60, P <
0.0001; Fig. 2D). Post hoc analysis showed a significant decrease
in total time spent eating only in saline/OEA (5 and 10 mg/kg)
groups, compared with saline/vehicle and α-FMH/vehicle groups
(Fig. 2D). No significant effects of OEA were detected in his-
tamine-depleted mice compared with controls.
Effect of OEA on BSS Development in Histamine-Depleted Mice. We
tested the effect of histamine depletion on the BSS in mice in-
fused i.c.v. with α-FMH. Two-way ANOVA showed the signifi-
cant main effect of time for all of the behavioral categories
examined (eating, F7,273 = 8.06, P < 0.0001; locomotion, F7,273 =
13.72, P < 0.0001; resting, F7,273 = 18.15, P < 0.0001; and
grooming F7,273 = 4.13, P < 0.001). The time-dependent changes
in the evolution of these behavioral patterns reflect the gradual
decline of active behaviors (i.e., eating, grooming, and locomo-
tion) and the parallel increase in resting that typically describe
the expression of the BSS (Fig. 2 B, C, E, and F and Fig. S2 A
and B). One-way ANOVA for each behavior revealed a signifi-
cant treatment effect only for the duration of eating during 40-
min BSS testing (Fig. 2). Post hoc comparisons performed on the
duration of eating showed that only saline/OEA groups (Fig. 2E
and Fig. S2A) significantly reduced such activity compared with
saline/vehicle and α-FMH/vehicle groups (Fig. 2 B and C). No
significant effects of treatment on time spent resting [F5,39 =
0.79, not significant (n.s.)], motor (F5,39 = 0.59, n.s.), or grooming
activities (F5,39 = 1.81, n.s.) were found among all experimental
groups. As shown in BSS temporal patterns, both control groups
displayed an initial peak of feeding response followed by its
decline over time and subsequent transition to resting that
gradually increased around time bin T3 (Fig. 2 B and C). This
temporal pattern was different in mice with intact brain hista-
mine treated with OEA (Fig. 2E and Fig. S2A). OEA adminis-
tration produced a shifting of about 10-min of satiety and resting
cooccurrence, thus emphasizing the premature onset of satiety in
these animals with resting rapidly replacing eating activity (from
a T3 to T1 interval) in a basically well-preserved BSS structure.
In contrast, infusion of α-FMH prevented the effects of OEA on
satiety onset, as shown in Fig. 2F and Fig. S2B.
Functional Interaction Between OEA and Brain Histamine. In line with
the idea that OEA may exert its anorectic effects by modulating
brain histamine signaling, we found that systemic administration
of 10 mg/kg OEA increased histamine release from the prefrontal
cortex by ∼160%. Furthermore, OEA increased histamine release
only in 12 h-fasted but not in satiated mice (Fig. 3A). The increase
in histamine was transient and reached a maximum within 30 min
of OEA administration. Mean spontaneous histamine release was
not significantly different between experimental groups (53.7 ±
18.8 fmol per 30 min-fasted mice; 61.9 ± 33 fmol per 30 min-fed
ad libitum mice). We then measured histamine release from the
prefrontal cortex of freely moving mice that received i.p. admin-
istration of 3 mg/kg ABT-239. As shown in Fig. 3B, ABT-239
increased significantly histamine release by ∼130%. Histamine
mean spontaneous release was 49 ± 12 fmol/30 min. Co-
administration of OEA and ABT-239 further increased cor-
tical histamine release (Fig. 3B). Two-way ANOVA followed
by Bonferroni’s post hoc test showed a significant main effect
between groups [F(treatment)1,61 = 6.12, P < 0.01; F(time)8,61 = 11.6,
P < 0.0001; and F(treatment × time)8,61 = 1.37, n.s.]. Mean sponta-
neous histamine release was 34.3 ± 14.1 fmol/30 min. To ascertain
whether our α-FMH protocol caused a prolonged depletion of
releasable histamine stores from the mouse brain, we measured
histamine release from the mouse cortex 24 h after α-FMH i.c.v.
infusion. Cortical basal histamine contents of α-FMH–treated
mice were below detection level and no further histamine release
was elicited when mice received ABT-239 (Fig. 3B).
Fig. 2. Effects of OEA on the BSS in normal and
histamine-depleted mice. A and D show mean cu-
mulative PWM intake (±SEM) and mean time spent
in eating activity (±SEM) over the 40-min BSS, re-
spectively (n = 8 for each experimental group). A
and D also illustrate the temporal development of
eating, locomotion, grooming, and resting duration
(seconds) in saline/vehicle (B), α-FMH/vehicle (C),
saline/10 mg/kg OEA (E), and α-FMH/10 mg/kg OEA
(F). Represented on the x axes are eight time bins
(T) of 5 min each for a total of 40 min of BSS
analysis. ***P < 0.001, **P < 0.01, *P < 0.05 vs. re-
spective controls; ###P < 0.001 vs. α-FMH/vehicle
treated mice by one-way ANOVA and Bonferroni’s
test. Experiments were carried out during the
lights-off period (1900 h).
Fig. 3. Functional interaction between brain histamine and OEA. (A) Effect
of OEA administration on histamine release in the prefrontal cortex of freely
moving mice. Represented are means ± SEM of three fasted and four fed ad
libitum mice. (B) Effect of ABT-239 and OEA–ABT-239 on cortical histamine
release in freely moving mice. Represented are means ± SEM of four and five
mice, respectively. ABT-239 and OEA were administered i.p. separately and
α-FMH (5 μg) was administered i.c.v. Baseline histamine release was not
detectable in α-FMH–treated mice or during ABT-239 administration (dashed
line; n = 4). Experiments were carried out between 0900 and 1600 h. ***P <
0.001, **P < 0.01, *P < 0.05, vs. baseline values; ##P < 0.01 vs. ABT-239, two-
way ANOVA and Bonferroni’s test. For clarity, we reported only the signif-
icant differences vs. the last baseline sample before drug treatment, al-
though differences were significant vs. all baseline samples.
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OEA-Induced c-Fos Expression in HDC-KO Mice. In an attempt to
clarify how brain histamine deficit may prevent the satiety effect
of OEA, we measured c-Fos protein expression in the brain of
HDC-KO and WT mice following OEA administration. OEA
did not change c-Fos expression in the VMH (F3,18 = 0.081, n.s.)
of either WT or HDC-KO mice (Fig. S3C). As expected from
previous results obtained in rats (2), systemic OEA increased
significantly c-Fos expression in the PVN of WT mice (Fig. 4A;
F3,18 = 4.817, P < 0.05), whereas no differences were found in the
PVN of HDC-KO mice treated with vehicle or OEA. OEA
activates preferentially oxytocin neurons in the PVN (2). We
found that the percentage of oxytocin neurons expressing c-Fos
immunofluorescence was significantly lower in the PVN of OEA-
treated HDC-KO mice compared with OEA-treated WT mice
(Fig. 4B; P < 0.01), despite HDC-KO mice expressing higher
levels of oxytocin-positive neurons (WT = 166 ± 17 per square
millimeter vs. HDC-KO = 235 ± 14 per square millimeter; P <
0.01, unpaired t test). We also evaluated c-Fos expression in
limbic brain structures related to feeding behavior that receive
histaminergic innervation. Interestingly, in the nucleus accum-
bens that receives TMN input regulating exploratory behavior
(19) indispensable during food provisioning, OEA administra-
tion decreased c-Fos expression in both HDC-KO and WT mice
(F3,16 = 5,550, P < 0.05; Fig. S3B). In the infralimbic cortex,
which presumably implements arousal during appetitive behavior
(20) and provides the TMN with an essential input for the ap-
petitive function of histaminergic neurons (21), no differences
were found in c-Fos expression in either WT or HDC-KO mice
receiving OEA (Fig. S3A). We also observed a significant in-
crease in the percentage of c-Fos positive TMN neurons in
OEA- compared with vehicle-treated WT mice (OEA = 12.1 ±
1.35%; vehicle = 5.4 ± 1.4%; P < 0.01, unpaired t test; Fig. S4).
Discussion
Satiety-related signals are integrated at the cellular and system
level to give reliable and appropriate behavioral responses by
recruiting specific neuronal populations. OEA is synthesized
in several peripheral tissues and in the CNS (22) and in mam-
mals it has been described as a mediator of numerous metabolic
processes (4). OEA secreted by enterocytes serves as a fat-
sensing molecule that signals to satiety centers in the brain by
engaging vagus nerve sensory fibers (2, 4, 23) and suppresses
feeding by indirectly activating central oxytocin transmission in
the PVN and SON (3). However, it is not known if other neu-
rotransmitter systems integrate the peripheral signaling of OEA
with effector hypothalamic nuclei. Brain histamine affects feed-
ing behavior in a complex and not fully understood fashion (Fig.
5). It is fundamental for appetitive and aversive responses during
motivated behavior (24), and blockade of histamine H1R in the
hypothalamus is believed to be responsible for the weight gain
and metabolic dysregulation associated with the clinical use of
atypical antipsychotics (25). Several peptides and hormones—
such as leptin, corticotropin-, TSH-releasing hormones, and
nefastin-1—are satiety modulators acting, at least in part,
through histamine neurons activity (26–28). So far, there has
been no information regarding brain histamine taking part in the
anorexic effects of a modulator that, at the dose used in this study,
does not easily pass the blood–brain barrier. Here, by using dif-
ferent experimental settings, we invariably show that chronic or
acute histamine deficiency significantly attenuates OEA-induced
hypophagia. OEA’s effects in normal mice were not completely
reversed in HDC-KO or α-FMH–treated mice; indeed, it has been
recently proposed that an increase in peripheral fatty acid oxida-
tion and ketogenesis (29), as well as direct activation of the area
postrema (30), may contribute to OEA’s satiety effects. None-
theless, our use of different experimental settings gave compa-
rable results, supporting our view that OEA requires the integrity
of the histamine system to fully exert its hypophagic effect.
By monitoring the natural progression of feeding behavior and
its transition from eating to resting (i.e., satiety occurrence), the
BSS can provide a detailed analysis of the structure of feeding
behavior (18, 31). With respect to controls and α-FMH–injected
animals, OEA administration produced a temporal shifting to-
ward earlier intervals of the cooccurrence of eating and resting
behaviors. As illustrated by the preservation of the mutual
relationship between feeding and nonfeeding behaviors, OEA
induced a robust acceleration of satiety development without
disrupting the basic structure of the feeding cycle, whereas
histamine depletion abolished OEA-induced premature onset
of satiety. Also, the BSS allows the continuous and complete
Fig. 4. OEA-induced c-Fos expression in the hypothalamic PVN nucleus is
blunted in HDC-KO mice. (A) Brain coronal sections showing the effect of
vehicle or 10 mg/kg OEA on c-Fos protein expression in WT and HDC-KO mice
in PVN. (Scale bar: 100 μm.) Quantitative data are expressed in the bar graphs
as means ±SEM; *P < 0.05 vs. respective controls; #P < 0.05 vs. WT/OEA by one-
way ANOVA and Newman–Keuls test. (B) Immunohistochemical detection of
oxytocin and c-Fos in the PVN neurons of WT and HDC-KO mice treated with
OEA. (Scale bar: 50 μm.) The bar graph shows the percentage of oxytocin-
immunopositive neurons expressing c-Fos in OEA-treated WT and HDC-KO
mice; **P < 0.01, unpaired t test. n = 3–5 mice per experimental group.
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Fig. 5. Schematic drawing illustrating the putative interactions between
OEA and the central histaminergic system. Histamine neurons are localized
exclusively in the TMN of the posterior hypothalamus. Putative driver and
modulatory inputs to the TMN are designated according to (24). The broken
line designates presumed noradrenergic excitatory input from the NST to
the TMN. According to our hypothesis, OEA induces anorexia indirectly
stimulating histamine neurons in the TMN that project to the PVN. Activa-
tion of H1 and H2 receptors on feeding-related neurons in the PVN stim-
ulates oxytocin release. Histamine mediates suppression of food intake also
independently of OEA activating neurons in the VMH (47).
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examination of food intake and provides the most accurate
and detailed profile of feeding behavior, which are largely
superior to interval sampling techniques (18). To understand
which brain regions require histamine signaling for OEA-induced
hypophagia, we used c-Fos expression as marker of functional
activity. We found that lack of central histamine dampens OEA-
induced increase of c-Fos expression in oxytocin PVN neurons of
HDC-KO mice. The PVN integrates central and peripheral sa-
tiety signals, and H1R activation within the PVN has been
implicated in the neuronal regulation of appetite (Fig. 5), as
reported by decreased food intake following brain infusion of an
H1R agonist and increased c-Fos–like immunoreactivity within
the PVN (10). As pharmacological blockade of oxytocin recep-
tors in the brain prevents OEA anorexic effects (2), we believe
that histamine signaling on oxytocic PVN neurons is necessary
for OEA to fully exert its anorexic effect (Fig. 5). In this regard,
intranuclear and systemic release of oxytocin in response to
suckling is controlled by H1R and H2R within the PVN (32). It
was recently shown that noradrenergic NST–PVN projections
are involved in the activation of the hypothalamic oxytocin system
(33). In the TMN, α2A adrenoreceptors inhibit GABAergic trans-
mission to TMN neurons (34). It is conceivable that NST ad-
renergic fibers projecting to the TMN disinhibit TMN neurons
that in turn facilitate oxytocin release from the PVN to mediate
OEA’s prosatiety effect. Indeed, OEA increased c-Fos expres-
sion in a subgroup of TMN neurons, corresponding to the E2/E3
region in the mouse (35), that presumably are organized in
a functionally distinct circuit, impinging on selected brain
regions (36). c-Fos/HDC double-immunoreactive neurons in
food-deprived mice were few, which is consistent with results
obtained in rats under scheduled feeding (37). Interestingly,
we also found that OEA decreased neuronal activity within
the nucleus accumbens, as suggested by the low expression of
c-Fos in both HDC-KO and WT mice. Although in this con-
text we did not investigate this aspect further, it is interesting
that OEA restores gut-stimulated dopamine release in the
striatum of high-fat-fed rats increasing the reward value of un-
palatable, yet healthier food (38).
As brain histamine signaling in the PVN seems to be involved
in the acute effects of OEA on food consumption, we expec-
ted OEA to increase brain histamine release. Although technical
limitations do not allow performing in vivo microdialysis experi-
ments in the mouse PVN, we found in support of our hypothesis
that OEA increased cortical histamine release. We further tested
our hypothesis of brain histamine and OEA signaling func-
tional interactions by measuring food consumption after co-
administration of OEA and ABT-239, an H3R antagonist that
blocks both auto- and heteroreceptors and increases transiently
central release of histamine (12). Previous reports indicate that
H3R antagonists decrease food intake in several mammalian
species (reviewed in ref. 39), and here we show for the first time,
to our knowledge, such an effect for ABT-239 as well. Further-
more, ABT-239 increased cortical histamine, and in agreement
with feeding behavior, we observed a further increase in hista-
mine release following ABT-239 and OEA coadministration. In
our model we hypothesize that the hypophagic effects of OEA
and ABT-239 converge onto a common pathway, as also strongly
suggested by the isobolographic analysis of feeding behavior.
Histaminergic neurons may also induce hypophagia by targeting
other brain regions not affected by OEA, as is the case of leptin
that recruits histamine neurotransmission in the VMH (40). Also,
H3R antagonists and OEA regulate the release of several neuro-
transmitters other than histamine (41, 42), which may contribute
to the hypophagic effects independently of each other.
Recently, Torrealba and coworkers, using a behavioral pro-
tocol that separates the appetitive from the consummatory phase
of feeding, showed that histamine is differentially involved in
these two aspects of feeding behavior and that histamine is
important for motivation to eat (20, 21). Brain histamine then
seems to have different roles during food anticipatory responses
and food consumption (43). Such a complex orchestration may
be served by different histamine neuronal subpopulations that
are recruited at different times during the unfolding of a specific
behavior (36). Histamine neurons send broad projections within
the CNS that are organized in functionally distinct circuits im-
pinging on different brain regions (5). This implies independent
functions of subsets of histamine neurons according to their
terminal projections and their selective participation in different
aspects of behavioral responses. It is interesting that OEA elicits
histamine release from the cortex of hungry mice, but it is in-
effective in satiated animals. To our knowledge, this is the first
study to report that endogenous molecules can affect histamine
release differentially depending on the homeostatic state of the
animal. Whether histamine modulation in the cortex is relevant
for satiety to curb the incentive to eat is not known and certainly
deserves further study. Our study uncovers the role of brain
histamine in the signal transduction of OEA-mediated anorexi-
genic effects. We believe that understanding the role of the
histaminergic system in driving or modulating feeding behavior is
of therapeutic relevance; for instance, atypical antipsychotics are
thought to cause obesity by targeting histamine H1R (25), and
the orexigenic liability of these drugs parallels their binding po-
tency for histamine H1R (44, 45). Our results may contribute
to the development of more effective pharmacotherapy for the
management of obesity and ameliorate the safety profile of
centrally acting drugs. In this regard, the first H3R antagonist
for narcolepsy treatment was recently filed with the European
Medicine Agency (46), and its effectiveness in obese patients
may be assessed.
Materials and Methods
Animals. Male CD1 mice (8–9 wk, 25–35 g; Harlan), HDC-KO mice and WT
littermates (129/Sv background; see SI Materials and Methods for genotyp-
ing procedures and Fig. S5) grown in the animal facility of Dipartimento di
Neuroscienze, Psicologia, Area del Farmaco, e Salute del Bambino, were
housed in a temperature-controlled room (22 ± 1 °C) with a 12:12-h light–
dark cycle (lights on from 0700 to 1900 h), at constant temperature and
humidity with a standard diet (4RF21; Mucedola s.r.l.) and freely available
water. HDC-KO and WT were used at 2–3 mo of age (25–35 g). Mice were
handled for 1 wk before experiments. Housing, animal maintenance, and all
experiments were conducted in accordance with the Council Directive of the
European Community (86/609/EEC) of the Italian Decreto Legislativo 116
(1992) and National Institutes of Health guidelines on animal care and were
approved and supervised by a veterinarian.
Evaluation of Cumulative Food Consumption. Mice were tested during the
lights-on (0900 h) or lights-off (1900 h) cycle after 12 h food deprivation while
water remained available. A weighed amount of standard chow pellets was
placed in the food rack, and food consumption evaluated as the difference in
weight between that of initially provided food and that left in the rack,
including spillage in the cage. Mice were randomly assigned to the experi-
mental groups. The protocol for cerebral histamine depletion with α-FMH
i.c.v. injection is described in detail in SI Materials and Methods. Food con-
sumption was measured 15, 30, 45, and 60 min at 2, 4, 6, 8, 10, and 24 h after
food presentation. OEA was injected i.p. 15 min before food presentation in
12 h-fasted mice.
Isobolographic Analysis. The interaction between OEA and ABT-239 was
evaluated by coadministration of fixed ratios of each drug and by performing
an isobolographic analysis as detailed in SI Materials and Methods.
BSS Analysis and PWM Intake Assessment. Before α-FMH infusions, mice were
habituated for 7 d to a PWM diet. PWM was prepared daily as a mixture of
ground standard dry powdered food pellets in sweetened condensed milk
(Nestlè) solubilized in distilled water (1:1.5) and offered for 1 h/d (light cy-
cle). To minimize diet spillage, PWM was provided in special feeder beakers.
The BSS paradigm was performed as described previously (31) and in SI
Materials and Methods.
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Microdialysis Experiments. The effects of OEA and ABT-239 on brain histamine
release were evaluated in freely moving CD1 mice implanted with micro-
dialysis probes. For details on surgery, experimental protocols, and HPLC-
fluorimetric assay to quantify histamine, see SI Materials and Methods.
Experiments are also described in detail in SI Materials and Methods.
Immunohistochemistry. HDC-KO and WT littermates were maintained on the
standard chowdiet and fooddeprived for 12h (between2000hand800h;water
remained available) before i.p. administration of OEA (10 mg/kg) or saline. Two
hours after injections, mice were deeply anesthetized with chloral hydrate and
perfused transcardially with cold physiological saline followed by 4% (vol/vol)
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Brains were processed for
standard immunostaining as detailed in SI Materials and Methods.
Data and statistical analysis. Statistical analysis was performed using Prism
Software (GraphPad). Statistical significance of cumulative food consump-
tion and histamine release in microdialysis experiments were analyzed
by two-way ANOVA (time × treatment) with Bonferroni’s post hoc test.
Differences in c-Fos expression were determined by one-way ANOVA with
Newman–Keuls post hoc test. An unpaired t test was used to determine
statistical significance between theoretical and experimental ED50, as well as
differences between WT and HDC-KO mice in single- and double-labeled
PVN and TMN neurons. OEA and α-FMH effects on the duration of each BSS-
related behavior were assessed by two-way repeated-measures ANOVAs
with treatment (six levels) as the between-subject variable and time (eight
levels consisting in eight time bins of 5-min each, from T1 to T8) as the
within-subject variable, with Bonferroni’s post hoc test. The criterion value
for all statistical tests was P ≤ 0.05.
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SI Materials and Methods
Chemicals. Oleoylethanolamide (OEA) (Tocris Bioscience) was
dissolved in saline/polyethylene glycol/Tween80 (90/5/5, vol/vol/vol).
ABT-239 and α-fluoromethylhistidine (α-FMH) were synthesized
at Abbott Laboratories and dissolved in physiological saline. All
other reagents and solvents were of HPLC grade or the highest
grade available (Sigma).
Detection of the Histidine Decarboxylase Gene. In this study we used
inbred WT and histidine decarboxylase (HDC)-KO mice de-
scendent from the 129/Sv mouse strain generated by Ohtsu et al.
(1). The genotype was determined using the PCR protocol de-
scribed by Parmentier et al. (2). Briefly, the following primers
were used for WT allele amplification: 5′-AGT GAG GGA CTG
TGG CTC CAC GTC GAT GCT-3′ (complementary to HDC
gene 833–862) and 5′-TAC AGT CAA AGT GTA CCA TCA
TCC ACT TGG-3′ (HDC gene 980–951). The expected product
size was 147 bp. The mutant allele was amplified using primers
located within the Neor gene: 5′-AAA CAT CGC ATC GAG
CGA GCA CGT ACT CGG-3′ and 5′-ATG TCC TGA TAG
CGG TCC GCC ACA CCC AGC-3′, with an expected product
size of 244 bp. PCR was performed using 40 cycles of 30 s at
94 °C, 1 min at 64 °C, and 1 min at 72 °C, followed by 1 cycle at
72 °C for 10 min. The whole reaction mix was then fractionated
on a 2% agarose gel, and the PCR product was visualized by
ethidium bromide staining (Fig. S5).
Surgery and α-Fluoromethylhistidine Interocerebroventricular Infusion.
Mice were anesthetized with chloral hydrate (400 mg/kg) and
placed on a stereotaxic frame equipped with a mouse adapter and
ear bars (Kopf Instruments). Bilateral stainless steel cannulae
(7 mm in length, with an OD of 0.5 mm and ID of 0.25 mm) were
implanted in the lateral ventricle and fixed to the skull using dental
cement. The following coordinates were used according to the
mouse brain atlas (3): antero-posterior (AP), −0.3; lateral (L), ±1;
dorsoventral (DV), −1. After 7 d recovery, α-FMH was infused
into the ventricles with mice placed in their home cage. A stainless
steel injection microneedle (2.4 mm length, with an OD of 0.25 mm)
was connected through a polyethylene catheter to a 2-μL Hamilton
precision syringe and then lowered into the lateral cerebral ventricle
(DV 2.4 mm from bregma). α-FMH was delivered via an infusion
pump (0.5 μL per side) within 1 min. After infusion, the needle was
left in place for an additional 40 s. OEA was administered i.p. 24 h
after interocerebroventricular α-FMH infusion; controls received
equal volumes of saline.
Isobolographic Analysis. To measure food intake, we presented
a preweighed amount of food 15 min after systemic treatments
with ABT-239 (1, 3, 6, and 10 mg/kg), OEA (2.5, 5, 10, and
20 mg/kg), or vehicle to overnight-fasted CD1 mice. Food was
weighed again after 60 min. Inhibition of food consumption was
expressed as a percentage of food intake observed in vehicle-
treated mice in the same experimental session (4). ED50 values of
each compound were obtained from the corresponding log dose–
response curve. The interaction between ABT-239 and OEA was
evaluated by coadministration of fixed proportions of the ED50
obtained for each drug (ratio ABT239/OEA ranging between
0.25/0.25 to 2/2). For the drug mixture, experimental ED50
(ED50mix) and its associated confidence intervals were obtained
by linear regression analysis of the log dose–response curve and
compared with the theoretical additive (ED50add) obtained as
ED50add = f ×ED50ABT-239 + ð1− f Þ×ED50OEA; [S1]
and the variance was calculated as
VarED50add = f 2 ×VarED50ABT-239 + ð1− f Þ2 ×VarED50OEA;
[S2]
where f denotes a fraction of the corresponding ED50 in the drug
mixture (in our study f = 0.5). From these values, confidential
intervals were calculated and resolved according to the ratio of
the individual drug in the combination (5). When the drug com-
bination gives an experimental ED50 not statistically different
from the theoretical calculated ED50, the combination is inter-
preted as having an addictive effect (6). Additionally, to describe
the magnitude of interaction, we calculated the interaction index
according to the formula
γ= a=A+ b=B; [S3]
where A and B are the doses of OEA and ABT-239, respectively,
that give the specified effect and a and b are the combination
doses that cause the same effect. The quantities in Eq. S3 were
obtained from dose–response curves. The interaction index is
a quantitative marker for drug combination that indicates the
changed potency of the combination. γ-values ∼1 indicate addic-
tive interaction, values >1 imply an antagonistic interaction, and
values <1 indicate a synergistic interaction (7).
Microdialysis Experiments. CD1 mice were placed in a stereo-
taxic frame under deep anesthesia (5% isoflurane, in oxygen),
and a guide cannula (CMA 7; CMAMicrodialysis) was inserted in
the prefrontal cortex using the following coordinates according to
ref. 3: AP, 2.1; L, ±1.0; DV, 1.5. The cannula was fixed to the
skull using dental cement. Mice treated with α-FMH were in-
jected in the third ventricle during surgery (coordinates AP,
−0.3; L, −1; DV, 2.4). After surgery mice were housed singularly
to recover for 24 h. On the experiment day, the dialysis mem-
brane (2 mm, cut off 6 kDa, CMA 7 MD; CMA Microdialysis)
replaced the obstructor. The probe was perfused with Ringer’s
solution (NaCl 147 mM, CaCl2 2.2 mM, KCl 4.0 mM) for 2 h
stabilization (flux = 1 μL/min). After collection of three 30-min
baseline samples, OEA (5 mg/kg), ABT-239 (3 mg/kg), or both
were injected i.p. Experiments were performed between 900 and
1600 h. To prevent histamine degradation, 1.5 μL 5 mM HCl
were added to each sample. Dialysates were immediately frozen
and stored at −80 °C until analysis. Cannula placements were
verified by post mortem histology. Histamine contents in the
dialysates were determined by HPLC-fluorimetry as previously
described (8). The sensitivity limit was 10 fmol and the signal-to-
noise ratio was higher than 3. Histamine levels in the dialysate
samples were calculated in femtomols per 30 minutes.
Histological Verification. Mice were anesthetized with chloral hy-
drate (400 mg/kg i.p.) and 0.5 μL methylene blue per side was
injected in the cannulae. Mice were decapitated and their brains
removed and cut in halves along the bregma landmark to verify
appropriate dye perfusion through lateral and third ventricles.
Three animals were not properly infused and were excluded
from the final data analysis. The placement of microdialysis
membranes was verified post mortem. Rats were overdosed with
chloral hydrate and their brains removed and stored in 10%
formalin for 10 d. Forty-micron sections were then sliced on
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a cryostat, mounted on gelatin-coated slides, and then stained
with cresyl violet for light microscopic observation. Data from
rats in which the membranes were not correctly positioned were
discarded (less than 10%).
Behavioral Satiety Sequence Analysis and Palatable Wet Mesh Intake
Assessment.During palatable wet mesh (PWM) habituation, both
body weight and food intake were measured daily. According to
the behavioral satiety sequence (BSS) paradigm, eating duration
(biting or swallowing food), locomotor activity (movements
involving all four limbs and rearing), resting (immobility), and
grooming (face and body cleansing and scratching or biting the
coat) were continuously recorded for each subject and separately
scored. To avoid novel environment stress-induced anxiety, BSS-
related behaviors were recorded with animals in their home cages
between 1900 and 2000 h, for a total test of 40min in a soundproof
cubicle equipped with an infrared night-vision video recording
camera (Panasonic color CCTV Camera WV-CP310/G). Mice
were food deprived with water made available for 12 h before
each behavioral recording session and randomly assigned to the
experimental groups. OEA or vehicle were administered imme-
diately before onset of the dark cycle, and PWM was instantly
made available to animals. Each feeder was preweighed and the
difference between initial and final weights (after 40 min from
the start of BSS test) corresponded to the measure of PWM
intake. Onset, duration, and termination of each behavioral
event were coded under blind conditions, using EthoVision XT
(Version 7) software (Noldus Information Technology Inc.). To
analyze behavioral changes in BSS, the 40-min continuous re-
cording for each behavioral category was partitioned into 8 × 5
time bins.
Immunostaining Protocol. Brains were postfixed in the same so-
lution overnight (4 °C), and cryoprotected in 30% sucrose in PB.
Forty-micron-thick sections were cut on a cryostat and collected
in PB. Sections were preincubated in 0.75% H2O2 in PB for
30 min, in 0.2% BSA for 30 min, and then incubated overnight in
rabbit c-Fos primary antibodies (1:5,000; Sigma-Aldrich) at 4 °C.
The immunoreactive product was detected with an avidin-biotin
peroxidase system (Vectastain kit; Vector Laboratories). After
washing with PBS, sections were mounted on gelatin-coated
slides, dehydrated and coverslipped, and observed using an
Olympus BX40 microscope equipped with a Nikon DS-F1
camera. c-Fos immunopositive nuclei were counted bilaterally
using the Image J software (National Institutes of Health, Be-
thesda) on three to six sections per region per mouse and nor-
malized to a 1-mm2 area according to Munari et al. (8). Atlas
coordinates relative to bregma (3) for the sections analyzed were
from +1.70 to +1.34 for the infralimbic cortex, from +1.18 to
+0.86 for the nucleus accumbens, from −1.46 to −1.70 for the
ventromedial hypothalamus, from −0.82 to −0.94 for the para-
ventricular hypothalamic nucleus (PVN), and from −2.00 to −2.90
for the tuberomammillary nucleus (TMN) that encompass all re-
gion subgroups. Statistics were calculated on the average values
from three to six sections of individual animals. Thus, sample size
and statistics were based on the number of mice. For double-
labeling experiments, sections were preincubated with 2% nor-
mal goat and donkey sera (NGS and NDS; Jackson Immuno-
research) for 1 h and then incubated in a mixture of c-Fos
(1:3,000) and either mouse oxytocin (1:1,000; Millipore) or guinea
pig histidine decarboxylase (HDC) (1:400; Acris) primary anti-
bodies with 1% NGS and 1% NDS overnight at 4 °C. Sections
were then incubated in Cy3-conjugated donkey anti-rabbit IgG
(1:400; Jackson Immunoresearch) for 2 h at room temperature
and then in AlexaFluor 488-conjugated, goat anti-mouse IgG,
(1:300; Molecular Probes) for 2 h at room temperature. Sections
were mounted on glass slides, coverslipped with antifading me-
dium (Vectastain Vector Laboratories), and observed with a
Bio-Rad MCR 1024 ES confocal laser scanning microscope
(Bio-Rad) equipped with a krypton/argon laser source 15 mW
for fluorescence measurements as previously described (9). Single
(oxytocin/HDC) and double-labeled (oxytocin/HDC and c-Fos)
neurons were counted bilaterally in at least four sections in each
PVN/TMN from three mice per experimental group using Image J
software. Statistics were calculated on the average values of in-
dividual animals. Thus, sample size and statistics were based on the
number of mice.
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Fig. S1. Hypophagic effects induced by OEA (A), ABT-239 (B), and OEA–ABT-239 (i.e., combined) (C). Twelve hour-fasted CD1 mice received i.p. injection of
compounds. Error bars represent mean ± SEM of the quantity of food consumed 1 h after treatments. n = 5–9 mice. *P < 0.05, **P < 0.01, ***P < 0.001; one-
way ANOVA followed by Newman–Keuls.
Fig. S2. Temporal development of eating, locomotion, grooming, and resting duration in (A) saline/OEA (5 mg/kg) and (B) α-FMH/OEA (5 mg/kg). Represented
on the x axes are eight time bins (T) of 5 min each for a total of 40 min of BSS analysis. Experiments were performed at lights-off (1900 h).
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Fig. S3. OEA-induced c-Fos expression in WT and HDC-KO mice. Brain coronal sections showing the effect of vehicle (VEH) or OEA (10 mg/kg) in the infralimbic
cortex (A), the nucleus accumbens (B) and ventromedial hypothalamus (C ). (Scale bar: 100 μm.) Quantitative data are expressed in the bar graphs as means
±SEM; *P < 0.05 vs. respective controls’ one-way ANOVA followed by Newman–Keuls. n = 3–5 mice per experimental group.
Fig. S4. OEA-induced c-Fos expression in the TMN. Representative brain coronal sections showing the effect of 10 mg/kg OEA (A) or vehicle (B) on c-Fos
protein expression in the TMN of WT mice. This region corresponds the E2/E3 region in the rat (1). n = 3 per experimental group. (Scale bars: 100 μm.)
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Fig. S5. PCR confirmed the WT and HDC-KO genotypes. Lanes: 1, DNA marker; 2–11, HDC-KO mice; 12–17, WT mice. Note that all WT mice displayed a 147-bp
band corresponding to the HDC gene fragment, whereas all HDC-KO mice showed a 244-bp band corresponding to the Neor gene fragment.
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